PH4 Stock Overview
A biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CStone Pharmaceuticals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.23 |
| 52 Week High | HK$0.31 |
| 52 Week Low | HK$0.092 |
| Beta | 0.21 |
| 11 Month Change | -0.85% |
| 3 Month Change | 56.00% |
| 1 Year Change | -15.83% |
| 33 Year Change | -80.00% |
| 5 Year Change | -80.82% |
| Change since IPO | -83.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| PH4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.3% | -0.2% | 0.8% |
| 1Y | -15.8% | -16.9% | 9.1% |
Return vs Industry: PH4 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: PH4 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| PH4 volatility | |
|---|---|
| PH4 Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PH4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PH4's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 164 | Jason Yang | www.cstonepharma.com |
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company’s product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.
CStone Pharmaceuticals Fundamentals Summary
| PH4 fundamental statistics | |
|---|---|
| Market cap | €312.57m |
| Earnings (TTM) | -€18.73m |
| Revenue (TTM) | €60.08m |
5.2x
P/S Ratio-16.7x
P/E RatioIs PH4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PH4 income statement (TTM) | |
|---|---|
| Revenue | CN¥456.53m |
| Cost of Revenue | CN¥133.65m |
| Gross Profit | CN¥322.89m |
| Other Expenses | CN¥465.20m |
| Earnings | -CN¥142.31m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 70.73% |
| Net Profit Margin | -31.17% |
| Debt/Equity Ratio | 65.5% |
How did PH4 perform over the long term?
See historical performance and comparison